Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 224

1.

The beta-catenin pathway is activated in focal nodular hyperplasia but not in cirrhotic FNH-like nodules.

Rebouissou S, Couchy G, Libbrecht L, Balabaud C, Imbeaud S, Auffray C, Roskams T, Bioulac-Sage P, Zucman-Rossi J.

J Hepatol. 2008 Jul;49(1):61-71. doi: 10.1016/j.jhep.2008.03.013. Epub 2008 Apr 18.

2.
3.

A quantitative gene expression study suggests a role for angiopoietins in focal nodular hyperplasia.

Paradis V, Bièche I, Dargère D, Laurendeau I, Nectoux J, Degott C, Belghiti J, Vidaud M, Bedossa P.

Gastroenterology. 2003 Mar;124(3):651-9.

PMID:
12612904
4.

Clinicopathological features of focal nodular hyperplasia-like nodules in 130 cirrhotic explant livers.

Libbrecht L, Cassiman D, Verslype C, Maleux G, Van Hees D, Pirenne J, Nevens F, Roskams T.

Am J Gastroenterol. 2006 Oct;101(10):2341-6.

PMID:
17032200
5.

Telangiectatic focal nodular hyperplasia: a variant of hepatocellular adenoma.

Paradis V, Benzekri A, Dargère D, Bièche I, Laurendeau I, Vilgrain V, Belghiti J, Vidaud M, Degott C, Bedossa P.

Gastroenterology. 2004 May;126(5):1323-9.

PMID:
15131793
6.

Over-expression of glutamine synthetase in focal nodular hyperplasia: a novel easy diagnostic tool in surgical pathology.

Bioulac-Sage P, Laumonier H, Rullier A, Cubel G, Laurent C, Zucman-Rossi J, Balabaud C.

Liver Int. 2009 Mar;29(3):459-65. doi: 10.1111/j.1478-3231.2008.01849.x. Epub 2008 Sep 18.

PMID:
18803590
7.

Focal nodular hyperplasia-like areas in cirrhosis.

Quaglia A, Tibballs J, Grasso A, Prasad N, Nozza P, Davies SE, Burroughs AK, Watkinson A, Dhillon AP.

Histopathology. 2003 Jan;42(1):14-21.

PMID:
12493020
8.

Zonal gene expression in mouse liver resembles expression patterns of Ha-ras and beta-catenin mutated hepatomas.

Braeuning A, Ittrich C, Köhle C, Buchmann A, Schwarz M.

Drug Metab Dispos. 2007 Apr;35(4):503-7. Epub 2007 Jan 12.

PMID:
17220236
9.

Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders.

Zhu ZW, Friess H, Wang L, Abou-Shady M, Zimmermann A, Lander AD, Korc M, Kleeff J, Büchler MW.

Gut. 2001 Apr;48(4):558-64.

10.

Angiotensin I-converting enzyme (CD143) is down-regulated in focal nodular hyperplasia of the liver.

Gräntzdörffer I, Lendeckel U, Carl-McGrath S, Roessner A, Röcken C.

Am J Surg Pathol. 2004 Jan;28(1):84-8.

PMID:
14707868
11.

Glypican-3 expression distinguishes small hepatocellular carcinomas from cirrhosis, dysplastic nodules, and focal nodular hyperplasia-like nodules.

Libbrecht L, Severi T, Cassiman D, Vander Borght S, Pirenne J, Nevens F, Verslype C, van Pelt J, Roskams T.

Am J Surg Pathol. 2006 Nov;30(11):1405-11.

PMID:
17063081
12.

Molecular pathogenesis of focal nodular hyperplasia and hepatocellular adenoma.

Rebouissou S, Bioulac-Sage P, Zucman-Rossi J.

J Hepatol. 2008 Jan;48(1):163-70. Epub 2007 Oct 30. Review.

PMID:
17997499
13.

Unique hypervascular nodules in alcoholic liver cirrhosis: identical to focal nodular hyperplasia-like nodules?

Nakashima O, Kurogi M, Yamaguchi R, Miyaaki H, Fujimoto M, Yano H, Kumabe T, Hayabuchi N, Hisatomi J, Sata M, Kojiro M.

J Hepatol. 2004 Dec;41(6):992-8.

PMID:
15582133
14.

Revisiting the pathology of resected benign hepatocellular nodules using new immunohistochemical markers.

Bioulac-Sage P, Cubel G, Balabaud C, Zucman-Rossi J.

Semin Liver Dis. 2011 Feb;31(1):91-103. doi: 10.1055/s-0031-1272837. Epub 2011 Feb 22.

PMID:
21344354
15.

Quantitative evaluation of RASSF1A methylation in the non-lesional, regenerative and neoplastic liver.

Di Gioia S, Bianchi P, Destro A, Grizzi F, Malesci A, Laghi L, Levrero M, Morabito A, Roncalli M.

BMC Cancer. 2006 Apr 10;6:89.

16.

Clinical, morphologic, and molecular features defining so-called telangiectatic focal nodular hyperplasias of the liver.

Bioulac-Sage P, Rebouissou S, Sa Cunha A, Jeannot E, Lepreux S, Blanc JF, Blanché H, Le Bail B, Saric J, Laurent-Puig P, Balabaud C, Zucman-Rossi J.

Gastroenterology. 2005 May;128(5):1211-8.

PMID:
15887105
17.

Cholestasis is a marker for hepatocellular carcinomas displaying beta-catenin mutations.

Audard V, Grimber G, Elie C, Radenen B, Audebourg A, Letourneur F, Soubrane O, Vacher-Lavenu MC, Perret C, Cavard C, Terris B.

J Pathol. 2007 Jul;212(3):345-52.

PMID:
17487939
18.

Use of X-chromosome inactivation pattern and laser microdissection to determine the clonal origin of focal nodular hyperplasia of the liver.

Gong L, Li YH, Su Q, Li G, Zhang WD, Zhang W.

Pathology. 2009;41(4):348-55. doi: 10.1080/00313020902885029.

PMID:
19404847
19.

Expression of human telomerase reverse transcriptase in regenerative and precancerous lesions of cirrhotic livers.

Kotoula V, Hytiroglou P, Pyrpasopoulou A, Saxena R, Thung SN, Papadimitriou CS.

Liver. 2002 Feb;22(1):57-69.

PMID:
11906620
20.

MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations.

Ladeiro Y, Couchy G, Balabaud C, Bioulac-Sage P, Pelletier L, Rebouissou S, Zucman-Rossi J.

Hepatology. 2008 Jun;47(6):1955-63. doi: 10.1002/hep.22256.

Supplemental Content

Support Center